萬德斯(688178.SH):創投二期及一致行動人減持達到1%
格隆匯5月26日丨萬德斯(688178.SH)公佈,公司於2021年5月26日收到股東江蘇人才創新創業投資二期基金(有限合夥)(簡稱“創投二期”)及其一致行動人江蘇高投寧泰創業投資合夥企業(有限合夥)(簡稱“寧泰創投”)發來的《減持股份計劃進展吿知函》,自2021年2月18日-5月25日期間,創投二期及寧泰創投通過集中競價方式合計減持公司股份85.0155萬股,佔公司總股本的1.000%。
創投二期當前持有公司股份517.5329萬股,佔公司總股本的6.0888%;寧泰創投當前持有公司股份95.9132萬股,佔公司總股本的1.1284%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.